Last reviewed · How we verify
A Multicentre, Prospective, Non-interventional Trial Monitoring Therapy Pathways of Asthma Patients Treated With an Extra-fine ICS/LABA/LAMA Single-inhaler Triple Therapy in a Real-world Setting and Characterizing the Effects on Health-related Outcomes
TriMaximize, a non-interventional trial aims to collect prospective, longitudinal data from asthma patients under routine care, for whom their treating physician has decided to prescribe Trimbow® (beclometasone/formoterol/glycopyrronium).
Details
| Lead sponsor | Chiesi SAS |
|---|---|
| Status | UNKNOWN |
| Enrolment | 300 |
| Start date | 2023-03-03 |
| Completion | 2025-03 |
Conditions
- ASTHMA
Interventions
- Non-interventional
Primary outcomes
- To describe patient characteristics and therapy pathways for patients with a diagnosis of moderate to severe asthma who are treated with Trimbow in real world practice — 12 months
Descriptive analysis of patient demographics.
Countries
France